Joanne A. Hoogerland's research while affiliated with University of Groningen and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (19)
Objective
Carbohydrate Response Element Binding Protein (ChREBP) is a glucose 6-phosphate (G6P)-sensitive transcription factor that acts as a metabolic switch to maintain intracellular glucose and phosphate homeostasis. Hepatic ChREBP is well-known for its regulatory role in glycolysis, the pentose phosphate pathway, and de novo lipogenesis. The ph...
The liver is the primary organ responsible for the detoxification and metabolism of drugs. To date, a lack of preclinical models that accurately emulate drug metabolism by the human liver presents a significant challenge in the drug development pipeline, particularly for predicting drug efficacy and toxicity. In recent years, emerging microfluidic-...
Background
The nuclear receptor corepressor 1 (NCOR1) plays an important role in the regulation of gene expression in immunometabolic conditions by connecting chromatin-modifying enzymes, coregulators and transcription factors. NCOR1 has been shown to be involved in cardiometabolic diseases. Recently, we demonstrated that the deletion of macrophage...
The incidence of non-alcoholic fatty liver disease (NAFLD) has increased significantly over the past two decades. NAFLD ranges from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH) and predisposes to fibrosis and hepatocellular carcinoma (HCC). The importance of the immune system in hepatic physiology and in the progression of NAFLD i...
Objective
Glycogen storage disease type 1a (GSD Ia) is a rare inherited metabolic disorder caused by mutations in the glucose-6-phosphatase (G6PC1) gene. When untreated, GSD Ia leads to severe fasting-induced hypoglycemia. Although current intensive dietary management aims to prevent hypoglycemia, patients still experience hypoglycemic events. Poor...
Prevention of hypertriglyceridemia is one of the biomedical targets in Glycogen Storage Disease type 1a (GSD Ia) patients, yet it is unclear how hypoglycemia links to plasma triglyceride (TG) levels. We analyzed whole‐body TG metabolism in normoglycemic (fed) and hypoglycemic (fasted) hepatocyte‐specific glucose‐6‐phosphatase deficient (L‐G6pc‐/‐)...
Background and Aims
Bile acids (BAs) aid intestinal fat absorption and exert systemic actions by receptor-mediated signaling. BA receptors have been identified as drug targets for liver diseases. Yet, differences in BA metabolism between humans and mice hamper translation of pre-clinical outcomes. Cyp2c70-ablation in mice prevents synthesis of mous...
Background and aims:
Glycogen storage disease (GSD) type 1a is an inborn error of metabolism caused by defective glucose-6-phosphatase catalytic subunit (G6PC) activity. Patients with GSD 1a exhibit severe hepatomegaly due to glycogen and triglyceride (TG) accumulation in the liver. We have shown that the activity of carbohydrate response element...
Glycogen storage disease type 1a (GSD Ia) is an inborn error of metabolism caused by mutations in the G6PC gene, encoding the catalytic subunit of glucose-6-phosphatase. Early symptoms include severe fasting intolerance, failure to thrive and hepatomegaly, biochemically associated with nonketotic hypoglycemia, fasting hyperlactidemia, hyperuricemia...
It is well‐established that, besides facilitating lipid absorption, bile acids act as signaling molecules that modulate glucose and lipid metabolism. Bile acid metabolism, in turn, is controlled by several nutrient‐sensitive transcription factors. Altered intrahepatic glucose signaling in type 2 diabetes associates with perturbed bile acid synthesi...
Although it is clear that probiotics improve intestinal barrier function, little is known about the effects of probiotics on the aging intestine. We investigated effects of 10-week bacterial supplementation of Lactobacillus plantarum WCFS1, Lactobacillus casei BL23, or Bifidobacterium breve DSM20213 on gut barrier and immunity in 16-week-old accele...
Total file with differentially expressed genes after bacterial supplementations.
p>Although it is clear that probiotics improve intestinal barrier function, little is known about the effects of probiotics on the aging intestine. We investigated effects of 10-week bacterial supplementation of Lactobacillus plantarum WCFS1, Lactobacillus casei BL23, or Bifidobacterium breve DSM20213 on gut barrier and immunity in 16-week-old acce...
Probiotics influence the immune system, both at the local and systemic level. Recent findings suggest the relation between microbiota and the immune system alters with age. Our objective was to address direct effects of six bacterial strains on immune cells from young and aged mice: Lactobacillus plantarum WCFS1, Lactobacillus casei BL23, Lactococc...
Citations
... Microfluidic liver chips with flow/perfusion increase functional longevity, allowing chronic toxicity evaluation. Multi-omics biomarkers from these systems deliver poised indicators of emerging liver injury [80][81][82][83][84][85][86][87][88]. In silico modeling simulates patient-specific pharmacokinetics and mechanistic toxicity pathways in non-alcoholic fatty liver disease (NAFLD). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/435900543967232-1480938196211_Q64/Jingyuan-Fu-4.jpg)
... Interestingly, NCoR1 can play different roles in various conditions when genes are derepressed. NCoR1 deficiency can either be advantageous in controlling immune response, atherosclerosis, and liver metabolism by modulating inflammation and immunological factors [4][5][6][7][8], or disadvantageous in elevating the levels of pro-inflammatory cytokines and affecting apoptosis and cell differentiation [9][10][11][12][13]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281095512311-1667915422670_Q64/Martin-Geiger-3.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/800148250697730-1567781617837_Q64/Sara-Oppi.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/373208294412293-1465991199988_Q64/Sokrates-Stein.jpg)
... In chronic inflammatory diseases, such as MASLD, immune cells, including neutrophils, which are absent in the healthy tissue, are recruited to the liver. The role of these immune cells is not fully understood; however, they release toxic compounds, such as myeloperoxidase, which triggers additional production of reactive oxygen species, cytokines, and neutrophil extracellular traps (NETs), further aggravating the disease setting and progression [23]. In vivo studies revealed that mice lacking neutrophil elastase or myeloperoxidase had less liver damage. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272352936198173-1441945408668_Q64/David-Dombrowicz.jpg)
... Abnormal accumulation of intracellular glucose-6-phosphate drives glycogen synthesis by mass action (Adeva-Andany et al. 2016). "Increased liver triglyceride level" was associated with mutations of 3 genes in the gluconeogenesis-specific gene set, G6pc (MGI:95607), Pck1 (MGI:97501), and Slc25a13 (MGI:1354721), and is consistent with phenotypes associated with excess accumulation of glucose-6phosphate observed in a G6pc knockout mouse and in human patients with partial loss of G6PC function (Hoogerland et al. 2021). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/615254513946625-1523699515642_Q64/Fabian-Peeks-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/273640151318542-1442252304966_Q64/Brenda-Hijmans.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/962385732980736-1606462047606_Q64/Justina-Wolters.jpg)
... However, the report emphasizes that the evidence is insufficient to recommend an intermittent fasting diet as one of the nutritional therapy methods for diabetes or pre-diabetes (13). Furthermore, this diet model may cause hypoglycemia, ketonemia, dizziness and fatigue side effects (60,61). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/508797212782593-1498318116592_Q64/Arthur-Svendsen-2.jpg)
... Still, these processes are impaired by recurrent hypoglycemia and decreased pancreatic insulin secretion. These disrupted processes have been shown to correlate with the severity of disease in the setting of GSD-Ia (12). In addition to potentially inducing episodic acute pancreatitis, hyperlipidemia and increased glycogen stores lead to organomegaly, hepatic adenomas, and steatosis seen in this disorder. ...
... Indeed, mice lacking Cyp2c70 have liver damage ( Figure 1). Neonatal cholestasis has been documented, accompanied by elevated transaminases, cholangiocyte proliferation, and a pro-inflammatory and pro-fibrotic gene signature not seen in controls [6]. As Cyp2c70-deficient mice age, liver damage progresses with ductular reaction, hepatocyte necrosis, lymphocytes and neutrophils infiltration ultimately evolving to fibrosis in the livers of adult Cyp2c70-deficient mice [4,6]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281218257127-1705560547966_Q64/Anna-Palmiotti.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272480514342924-1441975825143_Q64/Folkert-Kuipers.jpg)
... In addition, activation of another transcription factor liver X receptor (LXR) by cellular oxysterols or pharmacological agonists can also activate SREBP-1c, facilitating DNL and hepatic TG secretion 30,31 . SREBP-1 activation is associated with increased VLDL-TG synthesis 32,33 , whereas ChREBP facilitates the expression of crucial proteins involved in VLDL lipidation and assembly (MTTP, TM6SF2) 34 . These observations underscore the strong link between DNL, VLDL synthesis and secretion, and dyslipidemia. ...
... In addition, ChREBP plays a direct role in regulating the enzymes encoded by genes carrying genetic risk variations associated with MASLD, such as TM6SF2 (57). TM6SF2 plays a crucial role in the synthesis of very low-density lipoprotein (VLDL) and has been identified as a target of ChREBP in the mouse liver. ...
... Using the L-G6pc1−/− model, Cho et al. showed that the causes for hepatic steatosis in hepatic G6Pase-ɑ deficiency include activation of carbohydrate response elementbinding protein (ChREBP) signaling, suppression in PPAR-α expression, and increase in PPAR-γ expression (Cho et al. 2017). L-G6pc1−/− mice were used (Saeed et al. 2020) to study the retinol metabolism in GSD1a. Hepatic retinol level was lower than control, even though the plasma retinol level was elevated. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272605735288880-1442005681023_Q64/Ali-Saeed-9.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272838959562771-1442061285640_Q64/J-Heegsma.jpg)
